AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- A study featuring DUNP19 (RAD 502) has shown promise in cancer treatment.
- The study showed that DUNP19 (RAD 502) can be used in multiple cancer models to halt tumor progression and prolong survival.
- The DUNP19 platform has significant potential to preselect patients with LRR15-expressing tumors for therapeutic dosing with 177Lu-DUNP19.
Shares of Radiopharm Theranostics Limited (ASX: RAD) surged by 10.45% during the early morning trading hours on 5 February 2024.
The jump in share price followed a company update, highlighting that a study featuring DUNP19 (RAD 502) has shown promise in cancer treatment. The study was undertaken by Dr. David Ulmert and colleagues from the University of California, Los Angeles.
About the study
The title of the study is –
The research shows for the first time the use of DUNP19 in multiple cancer models for identifying and targeting Leucine-Rich Repeat Containing 15 (LRRC15)-expressing cancers.
Data source: company update
Promising study outcomes
The findings propose a novel technique for treating and imaging various aggressive tumors that express LRRC15 and have limited targeted therapy options. The outcomes also give preliminary evidence of 177Lu-DUNP19 capability to target pathways included in immunotherapy resistance and a poor prognosis.
DUNP19 platform has significant potential to preselect patients with LRR15-expressing tumors for therapeutic dosing with 177Lu-DUNP19.
DUNP19 (RAD 501) is presently under pre-clinical investigation as a therapeutic monoclonal antibody labelled with the beta-emitting radioisotope Terbium-161.
RAD shares traded at AU$0.074 apiece at the time of writing on 5 February 2024.